YM155 Induces EGFR Suppression in Pancreatic Cancer Cells

YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model

(2011) Takahito Nakahara et al.   ANTI-CANCER DRUGS

Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263

(2011) Haikuo Tang et al.   BIOCHEMICAL PHARMACOLOGY

EGFR Nuclear Translocation Modulates DNA Repair following Cisplatin and Ionizing Radiation Treatment

(2011) G. Liccardi et al.   CANCER RESEARCH

Feedback regulation of EGFR signalling: decision making by early and delayed loops

(2011) Roi Avraham et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

A novel small-molecule disrupts Stat3 SH2 domain–phosphotyrosine interactions and Stat3-dependent tumor processes

(2010) Xiaolei Zhang et al.   BIOCHEMICAL PHARMACOLOGY

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant and platinum-based drugs

(2010) T Iwasa et al.   BRITISH JOURNAL OF CANCER

Sulindac Metabolites Induce Proteosomal and Lysosomal Degradation of the Epidermal Growth Factor Receptor

(2010) H. A. Pangburn et al.   Cancer Prevention Research

Role of Epidermal Growth Factor Receptor Degradation in Cisplatin-Induced Cytotoxicity in Head and Neck Cancer

(2010) Aarif Ahsan et al.   CANCER RESEARCH

Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models

(2010) Takahito Nakahara et al.   CANCER SCIENCE

Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma

(2010) Andre Cassell et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

(2010) Deric L. Wheeler et al.   Nature Reviews Clinical Oncology

EGFR Signaling and Drug Discovery

(2010) Georg Lurje et al.   ONCOLOGY

Survivin: A new target for anti-cancer therapy

(2009) Bríd M. Ryan et al.   CANCER TREATMENT REVIEWS

XIAP as a ubiquitin ligase in cellular signaling

(2009) S Galbán et al.   CELL DEATH AND DIFFERENTIATION

Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors

(2009) T. Satoh et al.   CLINICAL CANCER RESEARCH

Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer

(2009) Tetsuya Mitsudomi et al.   FEBS Journal

A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma

(2009) Karl D. Lewis et al.   INVESTIGATIONAL NEW DRUGS

Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer

(2009) Giuseppe Giaccone et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2

(2009) Hwang-Phill Kim et al.   PLoS One

Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways

(2008) Aisha Siddiqa et al.   BMC CANCER

Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non-Small Cell Lung Cancer Cell Lines

(2008) T. Iwasa et al.   CLINICAL CANCER RESEARCH